Physician profile
Paulette Johnson
NPI 1508308131
$15,052.95
in general payments reported to CMS, 2019-2025
72 companies · $3,367 in 2025
The $3,367 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,259 · 2022: $2,817 · 2023: $3,775 · 2024: $2,834 · 2025: $3,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,596 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,596.17 |
| Education | $380.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,583.78 | 2021-2025 | Enhertu, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $892.32 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Seagen INC. | $737.80 | 2021-2023 | Tivdak, Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $691.57 | 2022-2025 | |
| Abbvie INC. | $675.06 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $634.33 | 2021-2025 | Ninlaro, Iclusig |
| Merck Sharp & Dohme LLC | $560.30 | 2022-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $541.66 | 2021-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $523.10 | 2021-2025 | Padcev, Veozah, Xtandi |
| Amgen INC. | $490.53 | 2021-2022 | |
| Glaxosmithkline, LLC. | $488.16 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $488.14 | 2021-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $455.41 | 2023-2025 | Libtayo |
| Daiichi Sankyo INC. | $404.23 | 2021-2025 | Injectafer, Enhertu, Datroway |
| Eisai INC. | $398.48 | 2021-2025 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $378.34 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Stemline Therapeutics INC. | $366.77 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $318.84 | 2021-2024 | Brukinsa, Tevimbra |
| Pfizer INC. | $288.32 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.82 | 2021-2022 | |
| Celgene Corporation | $238.10 | 2023-2025 | Reblozyl, Opdualag |
| Genentech USA, INC. | $228.94 | 2021-2024 | Tecentriq, Venclexta, Polivy |
| Rigel Pharmaceuticals, INC. | $207.72 | 2021-2024 | Tavalisse, Rezlidhia |
| Exelixis INC. | $201.19 | 2022-2025 | Cabometyx |
| Genzyme Corporation | $172.71 | 2021-2025 | |
| Taiho Oncology, INC. | $165.37 | 2022-2025 | |
| Kyowa Kirin, INC. | $154.87 | 2021-2025 | Poteligeo |
| Adc Therapeutics America, INC. | $141.82 | 2021-2024 | |
| Novo Nordisk INC | $140.01 | 2021-2024 | Wegovy |
| Sobi, INC | $137.13 | 2022-2025 | |
| Incyte Corporation | $119.96 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Morphosys, US INC. | $104.88 | 2022-2023 | Monjuvi |
| Array Biopharma INC | $101.20 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Adaptive Biotechnologies Corporation | $96.46 | 2022-2023 | Clonoseq |
| Beone Medicines USA, INC. | $95.49 | 2025 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $93.66 | 2023-2025 | Epkinly |
| Pharmacosmos Therapeutics INC. | $85.02 | 2021-2024 | Monoferric, Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $80.03 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $76.31 | 2022-2023 | Fotivda |
| Mirati Therapeutics, INC. | $75.51 | 2023-2024 | Krazati |
| Sumitomo Pharma America, INC. | $73.08 | 2023-2024 | Orgovyx, Gemtesa |
| Emd Serono, INC. | $70.66 | 2025 | |
| G1 Therapeutics, INC. | $64.31 | 2022-2023 | Cosela |
| Janssen Pharmaceuticals, INC | $60.85 | 2023 | Xarelto |
| Boston Scientific Corporation | $55.34 | 2022-2025 | General - Pain Management |
| Pharmaessentia USA Corporation | $55.22 | 2023-2025 | Besremi |
| Coherus Oncology, INC. | $53.36 | 2021-2023 | |
| Dova Pharmaceuticals | $51.76 | 2021 | |
| Jazz Pharmaceuticals INC. | $50.51 | 2023-2025 | |
| Acrotech Biopharma INC. | $50.24 | 2021-2023 | Beleodaq |
| Karyopharm Therapeutics INC. | $47.92 | 2022-2025 | Xpovio |
| Servier Pharmaceuticals LLC | $47.62 | 2021-2025 | |
| Tersera Therapeutics LLC | $42.12 | 2023 | Xermelo |
| Alexion Pharmaceuticals, INC. | $41.49 | 2024-2025 | Ultomiris |
| Myovant Sciences INC. | $38.49 | 2021-2022 | |
| Spectrum Pharmaceuticals INC. | $37.61 | 2023-2024 | Rolvedon |
| Puma Biotechnology, INC. | $34.18 | 2021-2025 | |
| Amag Pharmaceuticals, INC. | $33.66 | 2021 | |
| Secura Bio, INC. | $31.86 | 2022-2024 | Copiktra |
| Azurity Pharmaceuticals, INC. | $30.00 | 2025 | Danziten |
| Pharmacyclics LLC, An Abbvie Company | $25.49 | 2021 | |
| Geron Corporation | $19.74 | 2025 | Rytelo |
| Iovance Biotherapeutics, INC. | $19.57 | 2025 | Amtagvi |
| Recordati_rare_diseases_inc. | $17.98 | 2023 | Sylvant |
| Aimmune Therapeutics, INC. | $17.13 | 2025 | Zenpep |
| Novocure INC. | $16.50 | 2025 | Optune Lua (Novottf-200t) |
| Sun Pharmaceutical Industries INC. | $15.79 | 2024 | |
| Cti Biopharma Corp. | $15.71 | 2022 | |
| Epizyme, INC. | $14.75 | 2021 | |
| Agios Pharmaceuticals, INC. | $14.36 | 2023 | Pyrukynd |
| Shield Therapeutics INC | $13.80 | 2023 | Accrufer |
| Nestle Healthcare Nutrition INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
Enhertu $607Keytruda $538Libtayo $455Orserdu $367Opdivo $326Jaypirca $287Lenvima $279Trodelvy $275Tecvayli $255Darzalex $254Kisqali $243Ninlaro $213Imfinzi $198Venclexta $196Reblozyl $193Verzenio $189Cabometyx $182Tukysa $180Injectafer $172Opdualag $158Jemperli $143Scemblix $129Lonsurf $128Inqovi $128Talvey $127Epkinly $125Zejula $121Lynparza $121Tagrisso $118Calquence $108Lutathera $108Ojjaara $105Tavalisse $103Rezlidhia $103Brukinsa $103Erleada $103Ibrance $99.67Monjuvi $98.34Pluvicto $92.01Mektovi $82.36Braftovi $82.36Balversa $78.84Tivdak $77.09Padcev $76.04Krazati $75.51Piqray $73.01Tevimbra $67.75Orgovyx $66.98Tasigna $63.95Poteligeo $62.51Xarelto $60.85Retevmo $59.82Cosela $59.54Mekinist $56.97Tecentriq $55.65Besremi $55.22Nubeqa $53.24Besponsa $52.27Bosulif $52.27Adcetris $50.08Akeega $49.94Welireg $48.97Vonjo $48.03Pemazyre $46.69Xtandi $46.12Xermelo $42.12Ultomiris $41.49Monoferric $41.29Jakafi $40.42Fotivda $38.77Rolvedon $37.61Zepzelca $37.05Clonoseq $36.64Elrexfio $35.67Veozah $35.37Airsupra $35.22General - Pain Management $33.77Doptelet $33.37Rybrevant $32.80Comirnaty $32.67Xpovio $31.54Carvykti $31.41Talzenna $31.26Imbruvica $31.02Danziten $30.00Inlyta $29.29Keytruda Qlex $27.18Fabhalta $26.26Iclusig $25.89Gemtesa $24.17Polivy $23.06Evusheld $23.02Copiktra $22.76Tibsovo $22.16Lorbrena $20.94Zynyz $20.82Wayrilz $20.67Nerlynx $20.41Rytelo $19.74Amtagvi $19.57
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paulette Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.